155 related articles for article (PubMed ID: 32259555)
1. Drug interaction study of flavonoids toward OATP1B1 and their 3D structure activity relationship analysis for predicting hepatoprotective effects.
Fan X; Bai J; Hu M; Xu Y; Zhao S; Sun Y; Wang B; Hu J; Li Y
Toxicology; 2020 May; 437():152445. PubMed ID: 32259555
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the interactions between flavonoids and human organic anion transporting polypeptide 1B1 using fluorescent substrate and 3D-QSAR analysis.
Xiang Y; Liu S; Yang J; Wang Z; Zhang H; Gui C
Biochim Biophys Acta Biomembr; 2020 May; 1862(5):183210. PubMed ID: 32006472
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of hepatic uptake transporters by flavonoids.
Mandery K; Balk B; Bujok K; Schmidt I; Fromm MF; Glaeser H
Eur J Pharm Sci; 2012 May; 46(1-2):79-85. PubMed ID: 22394605
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory interaction of flavonoids with organic anion transporter 3 and their structure-activity relationships for predicting nephroprotective effects.
Wang FH; Tan HX; Hu JH; Duan XY; Bai WT; Wang XB; Wang BL; Su Y; Hu JP
J Asian Nat Prod Res; 2024 Mar; 26(3):353-371. PubMed ID: 37589480
[TBL] [Abstract][Full Text] [Related]
5. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver.
Sato T; Yamaguchi H; Kogawa T; Abe T; Mano N
J Pharm Pharm Sci; 2014; 17(4):475-84. PubMed ID: 25579430
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory interaction of flavonoids with organic cation transporter 2 and their structure-activity relationships for predicting nephroprotective effects.
Tan H; Wang F; Hu J; Duan X; Bai W; Wang X; Wang B; Su Y; Hu J
J Appl Toxicol; 2023 Oct; 43(10):1421-1435. PubMed ID: 37057715
[TBL] [Abstract][Full Text] [Related]
7. SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury.
Li LM; Chen L; Deng GH; Tan WT; Dan YJ; Wang RQ; Chen WS
Mol Med Rep; 2012 Jul; 6(1):75-82. PubMed ID: 22562052
[TBL] [Abstract][Full Text] [Related]
8. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of inhibitory effects of flavonoids on breast cancer resistance protein (BCRP): From library screening to biological evaluation to structure-activity relationship.
Fan X; Bai J; Zhao S; Hu M; Sun Y; Wang B; Ji M; Jin J; Wang X; Hu J; Li Y
Toxicol In Vitro; 2019 Dec; 61():104642. PubMed ID: 31493543
[TBL] [Abstract][Full Text] [Related]
10. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators.
Wang X; Wolkoff AW; Morris ME
Drug Metab Dispos; 2005 Nov; 33(11):1666-72. PubMed ID: 16081670
[TBL] [Abstract][Full Text] [Related]
11. [The interactions between natural products and OATP1B1].
Shi MZ; Liu Y; Bian JL; Jin M; Gui CS
Yao Xue Xue Bao; 2015 Jul; 50(7):848-53. PubMed ID: 26552146
[TBL] [Abstract][Full Text] [Related]
12. Potential Risk of Food-Drug Interactions: Citrus Polymethoxyflavones and Flavanones as Inhibitors of the Organic Anion Transporting Polypeptides (OATP) 1B1, 1B3, and 2B1.
Bajraktari-Sylejmani G; Weiss J
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):809-815. PubMed ID: 32661908
[TBL] [Abstract][Full Text] [Related]
13. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.
Gozalpour E; Greupink R; Wortelboer HM; Bilos A; Schreurs M; Russel FG; Koenderink JB
Mol Pharm; 2014 Jun; 11(6):1844-55. PubMed ID: 24754247
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1).
van de Steeg E; van der Kruijssen CM; Wagenaar E; Burggraaff JE; Mesman E; Kenworthy KE; Schinkel AH
Drug Metab Dispos; 2009 Feb; 37(2):277-81. PubMed ID: 19022939
[TBL] [Abstract][Full Text] [Related]
15. Glycyrrhizin has a high likelihood to be a victim of drug-drug interactions mediated by hepatic organic anion-transporting polypeptide 1B1/1B3.
Dong J; Olaleye OE; Jiang R; Li J; Lu C; Du F; Xu F; Yang J; Wang F; Jia W; Li C
Br J Pharmacol; 2018 Sep; 175(17):3486-3503. PubMed ID: 29908072
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1.
Patik I; Székely V; Német O; Szepesi Á; Kucsma N; Várady G; Szakács G; Bakos É; Özvegy-Laczka C
Sci Rep; 2018 Feb; 8(1):2630. PubMed ID: 29422623
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.
Durmus S; Lozano-Mena G; van Esch A; Wagenaar E; van Tellingen O; Schinkel AH
Mol Pharm; 2015 Dec; 12(12):4259-69. PubMed ID: 26474710
[TBL] [Abstract][Full Text] [Related]
18. In Silico and in Vitro Assessment of OATP1B1 Inhibition in Drug Discovery.
Danielson ML; Sawada GA; Raub TJ; Desai PV
Mol Pharm; 2018 Aug; 15(8):3060-3068. PubMed ID: 29927611
[TBL] [Abstract][Full Text] [Related]
19. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
Treiber A; Schneiter R; Häusler S; Stieger B
Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
[TBL] [Abstract][Full Text] [Related]
20. Short-lasting inhibition of hepatic uptake transporter OATP1B1 by tyrosine kinase inhibitor pazopanib.
Taguchi T; Masuo Y; Sakai Y; Kato Y
Drug Metab Pharmacokinet; 2019 Dec; 34(6):372-379. PubMed ID: 31703927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
